Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedFeb 12, 2026
DataAggregated Company Financials
Companies152
  • 7D0.5%
  • 3M-7.1%
  • 1Y-9.1%
  • YTD-2.0%

The Healthcare is pretty flat in the last 7 days, but Swedish Orphan Biovitrum has stood out, gaining 14%. As for the longer term, the industry has declined 9.1% in the last year. Earnings are forecast to grow by 26% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 12 Feb 2026SEK 571.5bSEK 230.1b-SEK 1,744,263,596.7432.5x-327.6x2.5x
Sat, 10 Jan 2026SEK 599.8bSEK 230.2bSEK 3.7b41x163.5x2.6x
Mon, 08 Dec 2025SEK 595.3bSEK 230.8bSEK 3.6b42.6x167.7x2.6x
Wed, 05 Nov 2025SEK 602.2bSEK 228.4bSEK 3.4b45.4x179.2x2.6x
Fri, 03 Oct 2025SEK 607.6bSEK 227.2bSEK 6.6b42.9x91.9x2.7x
Sun, 31 Aug 2025SEK 623.6bSEK 227.3bSEK 6.6b46.8x95x2.7x
Tue, 29 Jul 2025SEK 637.0bSEK 226.8bSEK 6.5b54x97.4x2.8x
Thu, 26 Jun 2025SEK 604.5bSEK 226.7bSEK 5.9b44.9x103.2x2.7x
Sat, 24 May 2025SEK 587.2bSEK 226.0bSEK 6.6b37x88.8x2.6x
Mon, 21 Apr 2025SEK 548.1bSEK 221.4bSEK 5.2b33.6x106.2x2.5x
Wed, 19 Mar 2025SEK 555.1bSEK 206.3bSEK 4.9b37x113.3x2.7x
Fri, 14 Feb 2025SEK 605.5bSEK 206.6bSEK 2.0b45.5x302.5x2.9x
Sun, 12 Jan 2025SEK 581.1bSEK 202.7b-SEK 2,498,780,680.0441.1x-232.5x2.9x
Tue, 10 Dec 2024SEK 573.6bSEK 202.5b-SEK 2,457,274,996.9837.3x-233.4x2.8x
Thu, 07 Nov 2024SEK 520.9bSEK 200.0b-SEK 2,882,322,661.7237.1x-180.7x2.6x
Sat, 05 Oct 2024SEK 607.5bSEK 200.2b-SEK 2,782,910,611.7639.8x-218.3x3x
Mon, 02 Sep 2024SEK 616.7bSEK 200.0b-SEK 2,803,885,491.0341.3x-219.9x3.1x
Wed, 31 Jul 2024SEK 588.0bSEK 199.8b-SEK 2,850,110,248.7341.1x-206.3x2.9x
Fri, 28 Jun 2024SEK 559.6bSEK 195.7b-SEK 3,063,087,249.0336.6x-182.7x2.9x
Sun, 26 May 2024SEK 553.7bSEK 196.1b-SEK 2,796,375,625.7836.5x-198x2.8x
Tue, 23 Apr 2024SEK 509.5bSEK 193.1b-SEK 3,154,359,283.3344.5x-161.5x2.6x
Thu, 21 Mar 2024SEK 514.8bSEK 192.5b-SEK 3,668,807,386.0344.1x-140.3x2.7x
Sat, 17 Feb 2024SEK 516.8bSEK 191.4b-SEK 4,057,378,134.3249.9x-127.4x2.7x
Mon, 15 Jan 2024SEK 558.9bSEK 191.5b-SEK 965,181,563.0048.1x-579.1x2.9x
Wed, 13 Dec 2023SEK 498.6bSEK 190.4b-SEK 1,068,107,791.0049.1x-466.8x2.6x
Fri, 10 Nov 2023SEK 473.9bSEK 190.1b-SEK 1,121,761,379.0050x-422.5x2.5x
Sun, 08 Oct 2023SEK 447.6bSEK 185.1b-SEK 2,032,952,939.0034.3x-220.2x2.4x
Tue, 05 Sep 2023SEK 466.5bSEK 185.5b-SEK 2,035,846,548.0038.4x-229.1x2.5x
Thu, 03 Aug 2023SEK 474.2bSEK 184.0b-SEK 988,067,967.0040x-480x2.6x
Sat, 01 Jul 2023SEK 480.3bSEK 179.2b-SEK 795,007,793.0044.7x-604.2x2.7x
Mon, 29 May 2023SEK 515.6bSEK 178.7b-SEK 548,140,751.0044.1x-940.7x2.9x
Wed, 26 Apr 2023SEK 510.1bSEK 173.2b-SEK 1,493,622,211.0035x-341.5x2.9x
Fri, 24 Mar 2023SEK 483.5bSEK 172.3b-SEK 1,416,096,910.0035.7x-341.4x2.8x
Sun, 19 Feb 2023SEK 504.2bSEK 169.7b-SEK 524,771,408.0037.2x-960.7x3x
Price to Earnings Ratio

-960.7x


Total Market Cap: SEK 504.2bTotal Earnings: -SEK 524,771,408.00Total Revenue: SEK 169.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -168.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swedish Healthcare industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 2.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 11% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market0.12%
Healthcare0.53%
Biotech7.28%
Pharma-0.24%
Healthcare Services-1.25%
Medical Equipment-2.55%
Life Sciences-8.34%
Healthtech-10.54%
Industry PE
  • Investors are most optimistic about the Healthtech industry even though it's trading below its 3-year average PE ratio of 117x.
    • Analysts are expecting annual earnings growth of 17.6%, which is lower than the prior year's growth of 46.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 36% over the next 5 years.
  • However this is lower than its past earnings growth rate of 97% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 408.2013.9%
+SEK 17.6b		27.3%PE295.2x
ATT AttendoSEK 100.6010.9%
+SEK 1.4b		58.4%PE17.9x
MCOV B MedicoverSEK 214.004.1%
+SEK 1.3b		3.4%PE39.5x
BIOA B BioArcticSEK 318.203.3%
+SEK 904.1m		46.6%PE28.2x
MVIR MedivirSEK 0.96115.0%
+SEK 317.1m		-54.9%PS133.3x

Latest News

BONEX
SEK 167.90
Bonesupport Holding
7D
-7.6%
1Y
-51.3%

Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
ALIF B
SEK 137.50
AddLife
7D
-11.5%
1Y
-20.9%

Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings

Feb 12
Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings
MCOV B
SEK 214.00
Medicover
7D
4.1%
1Y
3.4%
ASKER
SEK 65.26
Asker Healthcare Group
7D
-12.1%
1Y
n/a
BIOA B
SEK 318.20
BioArctic
7D
3.3%
1Y
46.6%
SOBI
SEK 408.20
Swedish Orphan Biovitrum
7D
13.9%
1Y
27.3%
MVIR
SEK 0.96
Medivir
7D
115.0%
1Y
-54.9%
ATT
SEK 100.60
Attendo
7D
10.9%
1Y
58.4%

ATT: Updated Cash Returns And Margins Will Support Measured Future Prospects

Analysts have lifted their fair value estimate for Attendo from €90 to €110. They point to revised assumptions for revenue growth, profit margins and a slightly lower discount rate as key drivers of the change.
XVIVO
SEK 180.20
Xvivo Perfusion
7D
-12.7%
1Y
-60.6%

XVIVO: Higher Required Returns Will Still Support Attractive Upside Potential

Analysts have reduced their fair value estimate for Xvivo Perfusion to $385 from $425, citing slightly higher discount rate assumptions, more cautious views on revenue growth and profit margins, and a higher applied future P/E multiple. Valuation Changes Fair Value: Reduced from SEK 425 to SEK 385, reflecting a more conservative overall valuation input set.
CEVI
SEK 151.00
CellaVision
7D
7.1%
1Y
-22.2%
IMP A SDB
SEK 46.00
Implantica
7D
-5.3%
1Y
7.1%
IBT B
SEK 58.00
Infant Bacterial Therapeutics
7D
23.4%
1Y
35.8%
ARJO B
SEK 27.06
Arjo
7D
4.5%
1Y
-30.4%

ARJO B: Fair Value Will Reflect Lower Margins And Higher Required Returns

Analysts have trimmed their price target on Arjo from €32 to €28, citing updated assumptions for slightly lower revenue growth, slimmer profit margins and a higher discount rate, partly balanced by a higher future P/E multiple. Valuation Changes Fair Value Estimate reduced from €32 to €28, reflecting updated modelling inputs.
SECT B
SEK 187.30
Sectra
7D
-11.7%
1Y
-24.7%

SECT B: Cloud Contracts And Pathology Expansion Will Support Future Upside Potential

Analysts have reaffirmed their price target on Sectra at SEK 245.00, with only marginal tweaks to underlying model inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, supporting an unchanged view of fair value. What's in the News TUM Klinikum in Germany is expanding its Sectra enterprise imaging setup with pathology and ophthalmology modules under a five year contract covering up to 300,000 examinations per year, aimed at higher efficiency and closer collaboration across departments (Client announcement).
VIMIAN
SEK 25.14
Vimian Group
7D
-5.6%
1Y
-36.6%

VIMIAN: Future Leadership Change Will Support Execution Upside Despite Sector Downgrade

Narrative update Analysts have trimmed their price expectations for Vimian Group, with the updated fair value estimate easing from SEK 36.92 to SEK 33.76, as some now see lower future P/E assumptions and have adopted more cautious views similar to the recent SEK 27 price target cut in Street research. Analyst Commentary Recent research updates on Vimian Group have taken a more cautious tone, with the shift to an Underweight rating and a price target of SEK 27, down from SEK 37.
GETI B
SEK 199.85
Getinge
7D
-1.9%
1Y
-4.7%